This clinical scenario addresses uterine sarcoma occurring in the specific context of a perivascular epithelioid cell tumor (PEComa) of the female genital tract — a rare mesenchymal tumor subtype with a distinct evidence-based management pathway.
PEComas are rare mesenchymal tumors that can arise at multiple sites; gynecological PEComas account for approximately 25% of all cases. When uterine sarcoma develops within this tumor type, the rarity and particular biology of the lesion directly inform which treatment strategy is appropriate.
For metastatic disease, the first-line approach centers on a targeted class of agents directed at a specific intracellular signalling pathway; for selected patients whose tumors express hormone receptors, a hormonal strategy may additionally be considered. Full agent selection, eligibility criteria, and sequencing are detailed in the structured protocol.